Nuvalent To Present Patient-Reported Outcomes Data From The Phase 2 Portion Of The ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And Encore Pivotal Efficacy And Safety Data From The ARROS-1 Trial At 2025 IASLC ASCO North America Conference On Lung Cancer

Author: Benzinga Newsdesk | November 04, 2025 05:17pm

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the first presentation of patient-reported outcomes data from the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial of zidesamtinib, an investigational ROS1 inhibitor, as well as encore pivotal efficacy and safety data from the ARROS-1 trial, during two poster presentations at the 2025 IASLC ASCO North America Conference on Lung Cancer being held December 5-7, 2025 in Chicago.

Posted In: NUVL